A Phase 1 interventional study of BGB-21447 in Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma and Relapsed Chronic Lymphocytic Leukemia, sponsored by BeOne Medicines. Terminated at 28 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by BeOne Medicines · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 196 studies in Lymphoma, Non-Hodgkin with a site in China — 83 open to participants now, 110 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.
Among the 196 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 96th largest by enrollment of the 183 interventional ones that give a count, is one of 23 that started in 2023, is one of 79 in phase 1, and was the 136th registered.
2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →83 of the 196 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:
Chinese PLA General Hospital · Sites in China
Ages 18–75
Chengdu Anticancer Bioscience, Ltd. · Sites in China
Ages 18–75
Chinese PLA General Hospital · Sites in China
Ages 18–75
Ruijin Hospital · Sites in China
Ages 18–75
Jecho Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
196 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 121 · Phase 2 67 · Phase 3 26 · Phase 4 3
First in 1997; this study’s year is marked. 23 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 58 across the 183 interventional studies, 1,000 across the 13 observational. Of the 45 that completed or were terminated, 12 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 196 have an industry lead sponsor. The 10 most frequent:
BeOne Medicines is the lead sponsor of 69 studies on the registry; 49 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
BeOne Medicines has 4 studies filed under Lymphoma, Non-Hodgkin — fewer than ten, so there is no comparison to draw.
26 of the studies in Lymphoma, Non-Hodgkin with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02972840Phase 3Acerta Pharma BVA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | 2027-02-15 |
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
Add all 26 to your calendar (.ics) → With an account.
Among the 196 studies in Lymphoma, Non-Hodgkin with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is testing the safety and tolerability of BGB-21447 monotherapy in participants with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study aims to determine the maximum tolerated dose (MTD), maximum administered dose (MAD), recommended Phase 2 dose (RP2D), and pharmacokinetic profile of the drug. Additionally, preliminary antitumor activity will be characterized. The study is divided into 2 main parts: Part 1 "Monotherapy Dose Finding" and Part 2 "Monotherapy Dose Optimization."
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed diagnosis (per World Health Organization [WHO] guidelines, unless otherwise noted) of one of the following:
Cohort A1 and Cohort A2:
R/R DLBCL (for Cohort A1 and Cohort A2.1)
Exclusion Criteria:
NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with R/R B-cell NHL (including diffuse large B-cell lymphoma \[DLBCL\], follicular lymphoma \[FL\], marginal zone lymphoma \[MZL\], transformed B-cell NHL (B-NHL), and Richter's transformation to DLBCL) will receive BGB-21447 once a day.
Drug: BGB-21447
Participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) will receive BGB-21447 once a day.
Drug: BGB-21447
Participants will receive BGB-21447 with two dose levels from Cohort A1 for further evaluation of safety and efficacy.
Drug: BGB-21447
Participants will receive BGB-21447 with two dose levels from Cohort A1 for further evaluation of safety and efficacy.
Drug: BGB-21447
BGB-21447 will be administered orally
Part 1: Number of participants with dose limiting toxicities (DLTs)
Number of participants with dose limiting toxicities, as defined in the study protocol.
Time frame: Up to approximately 1 month
Number of participants with adverse events (AEs)
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) assessed and graded based upon the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0).
Time frame: From the first dose of study drug to 30 days after the last dose or initiation of new anticancer therapy, whichever occurs first; up to approximately 12 months
Number of participants with Tumor Lysis Syndrome (TLS)
TLS will be determined via laboratory values and assessed by the investigator. In laboratory tumor lysis syndrome, 2 or more metabolic abnormalities must be present during the 24-hour period within 3 days before the start of study drug treatment or up to 7 days afterward. Clinical tumor lysis syndrome requires the presence of laboratory tumor lysis syndrome plus an increased creatinine level, seizures, cardiac dysrhythmia, or death.
Time frame: From the first dose of study drug to 30 days after the last dose or initiation of new anticancer therapy, whichever occurs first; up to approximately 12 months
Maximum observed plasma concentration (Cmax) After a Single Dose of BGB-21447
Time frame: Up to approximately 8 weeks
Area under the curve from time 0 to the last sampling time point within the dose interval (AUC0-t) After a Single Dose of BGB-21447
Time frame: Up to approximately 8 weeks
Area under the curve from time 0 extrapolated to infinity time (AUCinf) After a Single Dose of BGB-21447
Time frame: Up to approximately 8 weeks
Time to reach maximum observed plasma concentration (Tmax) After a Single Dose of BGB-21447
Time frame: Up to approximately 8 weeks
Apparent terminal elimination half-life (t1/2) After a Single Dose of BGB-21447
Time frame: Up to approximately 8 weeks
Apparent oral clearance (CL/F) After a Single Dose of BGB-21447
Time frame: Up to approximately 8 weeks
Apparent volume of distribution (Vz/F) After a Single Dose of BGB-21447
Time frame: Up to approximately 8 weeks
Steady state maximum observed plasma concentration (Cmax,ss) of BGB-21447
Time frame: Up to approximately 8 weeks
Steady state pre-dose trough concentration (Ctrough,ss) of BGB-21447
Time frame: Up to approximately 8 weeks
Steady state area under the curve from time 0 to the quantifiable concentration (AUClast,ss) of BGB-21447
Time frame: Up to approximately 8 weeks
Steady state time to reach maximum observed plasma concentration (Tmax,ss) of BGB-21447
Time frame: Up to approximately 8 weeks
Overall response rate (ORR)
Defined as the percentage of patients who achieve partial response or better for diffuse large B-cell lymphoma, marginal zone lymphoma, follicular lymphoma, transformed B-NHL, and Richter's transformation to DLBCL as per the Lugano Classification for non-Hodgkin lymphoma.
Time frame: Up to approximately 24 months
Duration of Response (DOR)
Defined as the time from the first response documentation to the date that progression is documented after treatment initiation or death due to any cause, whichever occurs first.
Time frame: Up to approximately 24 months
Time to response (TTR)
Defined as the time from treatment initiation to the first documentation of response.
Time frame: Up to approximately 24 months
Part 2: Progression-free survival (PFS)
Defined as the time from treatment initiation to the first documented disease progression or death due to any cause, whichever occurs first.
Time frame: Up to approximately 24 months
Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beonemedicines.com
No publications or documents are linked to this record.
Ran from Jun 2023 to primary completion in Jun 2026, 35 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.